(Q40568899)

21 September 2017

Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma (English)

1 reference

21 September 2017

1 reference

2

Vernon K Sondak

1 reference

21 September 2017

Jeffrey Weber

1

1 reference

21 September 2017

Ronaldo Scotland

3

1 reference

21 September 2017

Ramila Phillip

4

1 reference

21 September 2017

Flora Wang

5

1 reference

21 September 2017

Valerie Rubio

6

1 reference

21 September 2017

Tor B Stuge

7

1 reference

21 September 2017

Susan G Groshen

8

1 reference

21 September 2017

Conway Gee

9

1 reference

21 September 2017

Georgia G Jeffery

10

1 reference

21 September 2017

Shirley Sian

11

1 reference

21 September 2017

Peter P Lee

12

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

21 September 2017

1 reference

21 September 2017

97

1 reference

21 September 2017

186-200

1 reference

21 September 2017

1

1 reference

Tumor antigens recognized by T cells

21 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Human tumor antigens for cancer vaccine development

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

DNA immunization induces protective immunity against B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Effects of continuous high dose rhGM-CSF infusion on human monocyte activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Skin test to assess virus-specific cytotoxic T-cell activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Use of a skin test assay to determine tumor-specific CD8+ T cell reactivity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Phenotypic analysis of antigen-specific T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Short-term kinetics of tumor antigen expression in response to vaccination

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Induction of a protective immunity against Schistosoma mansoni with ovalbumin-coupled Sm37-5 coadsorbed with granulocyte-macrophage colony stimulating factor (GM-CSF) or IL-12 on alum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Granulocyte-macrophage colony-stimulating factor as immunomodulating factor together with influenza vaccination in stem cell transplant patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Tumors derived from antigen presenting cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus--rabbit model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Status of activation of circulating vaccine-elicited CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Mechanisms of cytokine synergy essential for vaccine protection against viral challenge

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11045

7 January 2021

Identifiers

DOI

10.1002/CNCR.11045

1 reference

21 September 2017

1 reference